Search hospitals > Texas > Lubbock
Texas Retina Associates
Claim this profileLubbock, Texas 79424
Global Leader in Macular Edema
Global Leader in Diabetic Macular Edema
Conducts research for Retinal Disease
Conducts research for Diabetic Retinopathy
Conducts research for Swelling
21 reported clinical trials
1 medical researcher
Summary
Texas Retina Associates is a medical facility located in Lubbock, Texas. This center is recognized for care of Macular Edema, Diabetic Macular Edema, Retinal Disease, Diabetic Retinopathy, Swelling and other specialties. Texas Retina Associates is involved with conducting 21 clinical trials across 17 conditions. There are 1 research doctors associated with this hospital, such as Michel Shami, MD.Top PIs
Clinical Trials running at Texas Retina Associates
Retinal Disease
Age-Related Macular Degeneration
Vision Impairment
Low Vision
Radiation Retinopathy
Visual Impairment
Premature Birth
Retinopathy of Prematurity
Diabetic Retinopathy
Macular Pucker
Faricimab or Fluocinolone Acetonide
for Vision Loss
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Recruiting2 awards Phase 38 criteria
Bevacizumab
for Retinopathy of Prematurity
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Recruiting1 award Phase 22 criteria
Fenofibrate
for Diabetic Retinopathy
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the drug safely. If this study demonstrates that fenofibrate is effective for reducing the onset of proliferative diabetic retinopathy (PDR) or and the results are adopted by the community of retina specialists, a new strategy to prevent vision threatening complications of diabetes could be widely adopted. Widespread use of an oral agent effective at reducing worsening of DR would decrease the numbers of patients who undergo more invasive and much more expensive treatment for DR and who are consequently at risk for side effects that adversely affect visual function. This study will also assess the relationship of glycemic variability, as measured by continuous glucose monitoring with DR outcomes. Ancillary studies will characterize functional and structural outcomes in this cohort.
Recruiting1 award Phase 35 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Texas Retina Associates?
Texas Retina Associates is a medical facility located in Lubbock, Texas. This center is recognized for care of Macular Edema, Diabetic Macular Edema, Retinal Disease, Diabetic Retinopathy, Swelling and other specialties. Texas Retina Associates is involved with conducting 21 clinical trials across 17 conditions. There are 1 research doctors associated with this hospital, such as Michel Shami, MD.